| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 75 | 2022 | 5257 | 4.600 |
Why?
|
| Tomography, X-Ray Computed | 74 | 2022 | 7783 | 4.380 |
Why?
|
| Carcinoma, Pancreatic Ductal | 28 | 2022 | 1828 | 2.290 |
Why?
|
| Radiology | 11 | 2023 | 426 | 2.050 |
Why?
|
| Radiography, Abdominal | 10 | 2020 | 126 | 1.850 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 6 | 2020 | 57 | 1.800 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 11 | 2020 | 382 | 1.690 |
Why?
|
| Pancreas | 14 | 2018 | 744 | 1.410 |
Why?
|
| Adenocarcinoma | 21 | 2020 | 7914 | 1.220 |
Why?
|
| Neuroendocrine Tumors | 6 | 2024 | 656 | 1.190 |
Why?
|
| Abdomen | 3 | 2020 | 347 | 1.150 |
Why?
|
| Image Processing, Computer-Assisted | 13 | 2019 | 1690 | 1.130 |
Why?
|
| Workflow | 3 | 2017 | 279 | 0.970 |
Why?
|
| Diagnostic Imaging | 16 | 2017 | 1174 | 0.960 |
Why?
|
| Quality Assurance, Health Care | 3 | 2016 | 596 | 0.940 |
Why?
|
| Pancreatic Cyst | 6 | 2015 | 111 | 0.880 |
Why?
|
| Pancreaticoduodenectomy | 12 | 2020 | 706 | 0.850 |
Why?
|
| Radiology Information Systems | 8 | 2002 | 119 | 0.830 |
Why?
|
| Peer Review, Research | 1 | 2023 | 66 | 0.820 |
Why?
|
| Multidetector Computed Tomography | 4 | 2017 | 147 | 0.780 |
Why?
|
| Magnetic Resonance Imaging | 25 | 2021 | 7895 | 0.780 |
Why?
|
| Editorial Policies | 1 | 2021 | 78 | 0.700 |
Why?
|
| Neoplasm Staging | 26 | 2021 | 14012 | 0.680 |
Why?
|
| Documentation | 2 | 2018 | 213 | 0.630 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 168 | 0.620 |
Why?
|
| Pancreatectomy | 6 | 2018 | 696 | 0.590 |
Why?
|
| Pancreatic Ducts | 4 | 2018 | 127 | 0.580 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 317 | 0.550 |
Why?
|
| Humans | 128 | 2024 | 270740 | 0.550 |
Why?
|
| Gastrinoma | 3 | 2014 | 25 | 0.540 |
Why?
|
| Neoadjuvant Therapy | 9 | 2022 | 5231 | 0.540 |
Why?
|
| Insulinoma | 3 | 2014 | 53 | 0.530 |
Why?
|
| Societies, Medical | 3 | 2021 | 1320 | 0.510 |
Why?
|
| Radiology Department, Hospital | 1 | 2016 | 53 | 0.500 |
Why?
|
| Reproducibility of Results | 13 | 2020 | 6177 | 0.480 |
Why?
|
| Endosonography | 9 | 2014 | 551 | 0.470 |
Why?
|
| Radiographic Image Enhancement | 8 | 2019 | 410 | 0.470 |
Why?
|
| Carcinoma, Acinar Cell | 2 | 2013 | 87 | 0.460 |
Why?
|
| Contrast Media | 14 | 2020 | 1499 | 0.450 |
Why?
|
| Computer Systems | 5 | 2001 | 113 | 0.440 |
Why?
|
| Liver Neoplasms | 7 | 2020 | 4821 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 1302 | 0.410 |
Why?
|
| Models, Organizational | 1 | 2012 | 69 | 0.400 |
Why?
|
| Diagnosis, Differential | 16 | 2020 | 4831 | 0.390 |
Why?
|
| Body Burden | 1 | 2011 | 64 | 0.390 |
Why?
|
| Signal-To-Noise Ratio | 4 | 2019 | 127 | 0.370 |
Why?
|
| Sensitivity and Specificity | 11 | 2020 | 5162 | 0.360 |
Why?
|
| Safety Management | 1 | 2011 | 135 | 0.360 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2009 | 909 | 0.360 |
Why?
|
| Radiation Protection | 1 | 2011 | 204 | 0.350 |
Why?
|
| Neoplasms, Second Primary | 2 | 2015 | 1388 | 0.340 |
Why?
|
| Digestive System Neoplasms | 2 | 2020 | 79 | 0.330 |
Why?
|
| History, 21st Century | 2 | 2021 | 419 | 0.330 |
Why?
|
| Peritoneal Neoplasms | 2 | 2015 | 859 | 0.320 |
Why?
|
| Retrospective Studies | 26 | 2022 | 39890 | 0.320 |
Why?
|
| Biliary Tract Diseases | 1 | 2009 | 65 | 0.310 |
Why?
|
| Aged, 80 and over | 26 | 2020 | 30998 | 0.310 |
Why?
|
| Quality Improvement | 1 | 2016 | 914 | 0.310 |
Why?
|
| Carcinoma, Papillary | 3 | 2018 | 566 | 0.310 |
Why?
|
| Middle Aged | 51 | 2022 | 90352 | 0.310 |
Why?
|
| Brain Neoplasms | 2 | 2021 | 4958 | 0.310 |
Why?
|
| Iodine | 2 | 2019 | 55 | 0.310 |
Why?
|
| Male | 55 | 2022 | 128315 | 0.290 |
Why?
|
| Deoxycytidine | 8 | 2022 | 1389 | 0.290 |
Why?
|
| Aged | 42 | 2020 | 73333 | 0.270 |
Why?
|
| Pelvic Neoplasms | 2 | 2005 | 199 | 0.270 |
Why?
|
| Adult | 41 | 2022 | 82040 | 0.260 |
Why?
|
| Algorithms | 9 | 2019 | 3891 | 0.260 |
Why?
|
| Internet | 5 | 2000 | 690 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 10400 | 0.260 |
Why?
|
| Positron-Emission Tomography | 4 | 2021 | 2197 | 0.260 |
Why?
|
| Female | 56 | 2022 | 148940 | 0.250 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2013 | 743 | 0.250 |
Why?
|
| Observer Variation | 3 | 2016 | 709 | 0.250 |
Why?
|
| Delivery of Health Care | 1 | 2012 | 855 | 0.250 |
Why?
|
| Carcinoid Tumor | 1 | 2007 | 282 | 0.240 |
Why?
|
| Paraganglioma | 1 | 2007 | 200 | 0.240 |
Why?
|
| Clinical Protocols | 2 | 2017 | 477 | 0.240 |
Why?
|
| Phantoms, Imaging | 4 | 2019 | 1330 | 0.240 |
Why?
|
| Evaluation Studies as Topic | 3 | 2017 | 452 | 0.220 |
Why?
|
| Urinary Calculi | 1 | 2003 | 29 | 0.220 |
Why?
|
| Flank Pain | 1 | 2003 | 10 | 0.220 |
Why?
|
| Publishing | 2 | 2023 | 194 | 0.220 |
Why?
|
| Kidney Diseases | 2 | 2006 | 694 | 0.210 |
Why?
|
| Lymphatic Metastasis | 4 | 2021 | 4963 | 0.210 |
Why?
|
| Triiodobenzoic Acids | 3 | 2015 | 69 | 0.210 |
Why?
|
| London | 1 | 2021 | 14 | 0.200 |
Why?
|
| Antineoplastic Protocols | 1 | 2022 | 36 | 0.200 |
Why?
|
| Radiography | 3 | 2023 | 1986 | 0.190 |
Why?
|
| User-Computer Interface | 2 | 2000 | 264 | 0.190 |
Why?
|
| Cadaver | 1 | 2021 | 202 | 0.190 |
Why?
|
| Splenic Rupture | 1 | 2000 | 6 | 0.180 |
Why?
|
| Preoperative Care | 3 | 2016 | 1567 | 0.180 |
Why?
|
| Radiologists | 1 | 2023 | 178 | 0.180 |
Why?
|
| Mental Recall | 1 | 2021 | 171 | 0.180 |
Why?
|
| Splenic Artery | 1 | 2000 | 54 | 0.180 |
Why?
|
| Aneurysm, Ruptured | 1 | 2000 | 44 | 0.180 |
Why?
|
| Hospital Information Systems | 1 | 2000 | 47 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2014 | 1347 | 0.170 |
Why?
|
| Neoplasm Metastasis | 6 | 2018 | 5315 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2022 | 16689 | 0.160 |
Why?
|
| Pancreatitis, Chronic | 1 | 2020 | 130 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 2400 | 0.160 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2011 | 689 | 0.160 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2016 | 442 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 690 | 0.160 |
Why?
|
| Gastrointestinal Diseases | 2 | 2022 | 608 | 0.160 |
Why?
|
| Kidney Neoplasms | 4 | 2013 | 3108 | 0.160 |
Why?
|
| History, 20th Century | 1 | 2021 | 544 | 0.150 |
Why?
|
| Software | 5 | 2017 | 1355 | 0.150 |
Why?
|
| Noise | 1 | 2017 | 33 | 0.140 |
Why?
|
| Education, Distance | 1 | 1999 | 100 | 0.140 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2018 | 107 | 0.140 |
Why?
|
| Pancreaticojejunostomy | 2 | 2013 | 14 | 0.140 |
Why?
|
| Thoracic Neoplasms | 1 | 2020 | 363 | 0.140 |
Why?
|
| Ligaments | 2 | 2009 | 42 | 0.140 |
Why?
|
| Photons | 1 | 2020 | 536 | 0.140 |
Why?
|
| Gastric Emptying | 2 | 2013 | 99 | 0.140 |
Why?
|
| Patient Selection | 5 | 2018 | 2025 | 0.130 |
Why?
|
| Prognosis | 11 | 2020 | 22505 | 0.130 |
Why?
|
| Gadolinium DTPA | 1 | 2016 | 173 | 0.130 |
Why?
|
| Genital Neoplasms, Female | 3 | 2017 | 794 | 0.130 |
Why?
|
| Pancreatic Diseases | 2 | 2009 | 113 | 0.130 |
Why?
|
| Abdomen, Acute | 1 | 1996 | 38 | 0.130 |
Why?
|
| Efficiency, Organizational | 1 | 2016 | 89 | 0.130 |
Why?
|
| Follow-Up Studies | 11 | 2018 | 15218 | 0.130 |
Why?
|
| Gaucher Disease | 1 | 1995 | 17 | 0.130 |
Why?
|
| Radiation Dosage | 2 | 2020 | 1042 | 0.120 |
Why?
|
| Intestinal Neoplasms | 2 | 2003 | 205 | 0.120 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2015 | 24 | 0.120 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 1995 | 43 | 0.120 |
Why?
|
| Hemangioma, Cavernous | 1 | 1995 | 32 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2000 | 745 | 0.120 |
Why?
|
| Databases as Topic | 2 | 2008 | 136 | 0.120 |
Why?
|
| Peritoneum | 1 | 2015 | 151 | 0.120 |
Why?
|
| Abdominal Neoplasms | 1 | 2017 | 251 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2016 | 585 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2018 | 647 | 0.120 |
Why?
|
| Mammography | 1 | 2000 | 1052 | 0.110 |
Why?
|
| Adenoma, Oxyphilic | 1 | 1994 | 76 | 0.110 |
Why?
|
| Choledochostomy | 1 | 2013 | 10 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 2650 | 0.110 |
Why?
|
| ROC Curve | 2 | 2007 | 1248 | 0.110 |
Why?
|
| Pancreatitis | 2 | 2008 | 295 | 0.110 |
Why?
|
| Tomography, Spiral Computed | 2 | 2004 | 128 | 0.110 |
Why?
|
| Combined Modality Therapy | 8 | 2019 | 9039 | 0.110 |
Why?
|
| Anastomotic Leak | 1 | 2013 | 83 | 0.100 |
Why?
|
| Liver | 3 | 2006 | 3086 | 0.100 |
Why?
|
| Stomach | 1 | 1995 | 402 | 0.100 |
Why?
|
| Fluoroscopy | 1 | 2013 | 223 | 0.100 |
Why?
|
| Postoperative Complications | 3 | 2018 | 5681 | 0.100 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2012 | 77 | 0.100 |
Why?
|
| Postoperative Hemorrhage | 1 | 2013 | 135 | 0.100 |
Why?
|
| Gastric Bypass | 1 | 2013 | 91 | 0.100 |
Why?
|
| Mesenteric Veins | 1 | 2012 | 83 | 0.100 |
Why?
|
| Veins | 1 | 2012 | 163 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 1340 | 0.100 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 166 | 0.100 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1994 | 402 | 0.090 |
Why?
|
| Hepatic Artery | 1 | 2012 | 255 | 0.090 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 550 | 0.090 |
Why?
|
| Radiopharmaceuticals | 2 | 2014 | 1341 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 661 | 0.090 |
Why?
|
| Colonic Neoplasms | 2 | 2013 | 1435 | 0.090 |
Why?
|
| Young Adult | 7 | 2018 | 22251 | 0.090 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 4960 | 0.090 |
Why?
|
| Portal Vein | 1 | 2012 | 363 | 0.090 |
Why?
|
| Capecitabine | 3 | 2022 | 390 | 0.080 |
Why?
|
| Cyst Fluid | 1 | 2009 | 22 | 0.080 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2009 | 35 | 0.080 |
Why?
|
| Liver Diseases | 2 | 2005 | 602 | 0.080 |
Why?
|
| CA-19-9 Antigen | 1 | 2010 | 155 | 0.080 |
Why?
|
| Albumins | 2 | 2022 | 262 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2020 | 6256 | 0.080 |
Why?
|
| United States | 6 | 2020 | 15861 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 5923 | 0.080 |
Why?
|
| Kidney | 3 | 2002 | 2121 | 0.080 |
Why?
|
| Texas | 3 | 2012 | 6449 | 0.080 |
Why?
|
| Celiac Artery | 1 | 2008 | 43 | 0.080 |
Why?
|
| Tissue Banks | 1 | 2008 | 51 | 0.080 |
Why?
|
| Mesenteric Arteries | 1 | 2008 | 64 | 0.070 |
Why?
|
| Models, Anatomic | 1 | 2009 | 146 | 0.070 |
Why?
|
| Mitotane | 1 | 2007 | 41 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2012 | 637 | 0.070 |
Why?
|
| Risk Factors | 4 | 2018 | 17888 | 0.070 |
Why?
|
| Genomics | 1 | 2018 | 2835 | 0.070 |
Why?
|
| Ultrasonography | 4 | 2009 | 1933 | 0.070 |
Why?
|
| Disease Progression | 1 | 2018 | 6867 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 5776 | 0.070 |
Why?
|
| Portal System | 1 | 2006 | 43 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2008 | 307 | 0.070 |
Why?
|
| Chemoradiotherapy | 3 | 2022 | 2027 | 0.060 |
Why?
|
| Microcomputers | 3 | 2002 | 35 | 0.060 |
Why?
|
| Computer Communication Networks | 3 | 2002 | 43 | 0.060 |
Why?
|
| Treatment Outcome | 10 | 2022 | 33737 | 0.060 |
Why?
|
| Biopsy | 3 | 2018 | 3484 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 375 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1996 | 1739 | 0.060 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2007 | 242 | 0.060 |
Why?
|
| Cholecystitis | 1 | 2004 | 59 | 0.060 |
Why?
|
| Information Storage and Retrieval | 2 | 2002 | 121 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2007 | 1260 | 0.060 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2005 | 303 | 0.060 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2002 | 173 | 0.060 |
Why?
|
| Vipoma | 2 | 2013 | 18 | 0.060 |
Why?
|
| DNA Adducts | 2 | 2014 | 213 | 0.060 |
Why?
|
| Image Enhancement | 2 | 2018 | 553 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 1823 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2005 | 303 | 0.050 |
Why?
|
| Emphysema | 1 | 2004 | 88 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2022 | 2101 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 841 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 3 | 2013 | 4048 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2018 | 2033 | 0.050 |
Why?
|
| Teaching Materials | 1 | 2002 | 23 | 0.050 |
Why?
|
| Cholangiography | 1 | 2001 | 34 | 0.050 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2004 | 318 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2018 | 2353 | 0.050 |
Why?
|
| Disease-Free Survival | 4 | 2020 | 10265 | 0.050 |
Why?
|
| Gallstones | 1 | 2001 | 64 | 0.050 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 2 | 2013 | 143 | 0.050 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2001 | 75 | 0.050 |
Why?
|
| Tertiary Care Centers | 2 | 2013 | 417 | 0.050 |
Why?
|
| Consensus | 2 | 2017 | 1106 | 0.050 |
Why?
|
| Rupture, Spontaneous | 1 | 2000 | 69 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2002 | 333 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2020 | 6764 | 0.040 |
Why?
|
| Iohexol | 1 | 2020 | 56 | 0.040 |
Why?
|
| Tomography | 1 | 2020 | 63 | 0.040 |
Why?
|
| Tomography, Emission-Computed | 1 | 2001 | 334 | 0.040 |
Why?
|
| Pelvis | 1 | 2002 | 381 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2005 | 625 | 0.040 |
Why?
|
| Satellite Communications | 1 | 1999 | 5 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2002 | 477 | 0.040 |
Why?
|
| X-Ray Film | 1 | 1999 | 31 | 0.040 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2001 | 224 | 0.040 |
Why?
|
| Fluorouracil | 3 | 2011 | 1990 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 670 | 0.040 |
Why?
|
| Prospective Studies | 5 | 2014 | 13414 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 1379 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 2014 | 1958 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 1034 | 0.040 |
Why?
|
| Photography | 1 | 1999 | 125 | 0.040 |
Why?
|
| Time Factors | 4 | 2018 | 13006 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2019 | 398 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2018 | 2250 | 0.040 |
Why?
|
| Mutation | 1 | 2018 | 15912 | 0.040 |
Why?
|
| Bile Duct Neoplasms | 1 | 2002 | 502 | 0.040 |
Why?
|
| Cholangiocarcinoma | 1 | 2002 | 504 | 0.040 |
Why?
|
| Education, Medical | 1 | 2002 | 344 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 3444 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 1060 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 984 | 0.030 |
Why?
|
| Angiography | 3 | 2005 | 350 | 0.030 |
Why?
|
| Data Collection | 1 | 1999 | 608 | 0.030 |
Why?
|
| Pneumoperitoneum | 1 | 1996 | 18 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 3530 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2020 | 9292 | 0.030 |
Why?
|
| Sodium Pertechnetate Tc 99m | 1 | 1995 | 4 | 0.030 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 4328 | 0.030 |
Why?
|
| Prevalence | 2 | 2015 | 3404 | 0.030 |
Why?
|
| Secretin | 1 | 2015 | 27 | 0.030 |
Why?
|
| Random Allocation | 1 | 2017 | 741 | 0.030 |
Why?
|
| Neoplasms | 2 | 2016 | 15927 | 0.030 |
Why?
|
| Ascites | 1 | 1996 | 213 | 0.030 |
Why?
|
| Pancreatic Fistula | 1 | 1995 | 102 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 89 | 0.030 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2014 | 16 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 1995 | 375 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 2014 | 129 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 4000 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 799 | 0.030 |
Why?
|
| Cricetinae | 1 | 1995 | 769 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 591 | 0.030 |
Why?
|
| Glucagonoma | 1 | 2013 | 12 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 1995 | 370 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1995 | 334 | 0.030 |
Why?
|
| Palliative Care | 1 | 2005 | 2178 | 0.030 |
Why?
|
| Biological Transport | 1 | 2014 | 626 | 0.030 |
Why?
|
| Arteriovenous Malformations | 1 | 2013 | 65 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 927 | 0.030 |
Why?
|
| Receptors, Somatostatin | 1 | 2013 | 94 | 0.030 |
Why?
|
| Japan | 1 | 2013 | 241 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2010 | 2271 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 2357 | 0.030 |
Why?
|
| Octreotide | 1 | 2013 | 131 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2013 | 118 | 0.030 |
Why?
|
| Heredity | 1 | 2012 | 26 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 2004 | 655 | 0.030 |
Why?
|
| Carcinoma | 1 | 2003 | 2610 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 103 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 749 | 0.020 |
Why?
|
| Survival Rate | 2 | 2018 | 12541 | 0.020 |
Why?
|
| Leukopenia | 1 | 2011 | 152 | 0.020 |
Why?
|
| Biomarkers | 1 | 2022 | 5051 | 0.020 |
Why?
|
| Adolescent | 5 | 2011 | 32767 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2013 | 418 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 2828 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 3240 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2010 | 4019 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 3707 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 1312 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2009 | 231 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1994 | 527 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 681 | 0.020 |
Why?
|
| Hepatectomy | 1 | 1995 | 1015 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 1994 | 705 | 0.020 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2008 | 43 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 2311 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 1430 | 0.020 |
Why?
|
| Taxoids | 1 | 2011 | 1015 | 0.020 |
Why?
|
| Pedigree | 1 | 2012 | 2042 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 7655 | 0.020 |
Why?
|
| Duodenal Neoplasms | 1 | 2008 | 138 | 0.020 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2008 | 152 | 0.020 |
Why?
|
| Ampulla of Vater | 1 | 2008 | 160 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2011 | 907 | 0.020 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2006 | 36 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 870 | 0.020 |
Why?
|
| Digestive System | 1 | 2006 | 121 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 2457 | 0.020 |
Why?
|
| Anemia | 1 | 2011 | 728 | 0.020 |
Why?
|
| Models, Biological | 1 | 2014 | 3194 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 2178 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2008 | 436 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 751 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 1059 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2014 | 3035 | 0.010 |
Why?
|
| APACHE | 1 | 2003 | 93 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 14849 | 0.010 |
Why?
|
| Duodenum | 1 | 2004 | 169 | 0.010 |
Why?
|
| Hospitalization | 1 | 2011 | 2167 | 0.010 |
Why?
|
| Bevacizumab | 1 | 2006 | 967 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2013 | 2328 | 0.010 |
Why?
|
| Urography | 1 | 2001 | 57 | 0.010 |
Why?
|
| Amylases | 1 | 2001 | 66 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2001 | 185 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2001 | 251 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2008 | 1857 | 0.010 |
Why?
|
| Cisplatin | 1 | 2008 | 2497 | 0.010 |
Why?
|
| Renal Artery Obstruction | 1 | 2000 | 40 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2004 | 1691 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2013 | 9470 | 0.010 |
Why?
|
| Vasculitis | 1 | 2000 | 72 | 0.010 |
Why?
|
| Printing | 1 | 1999 | 7 | 0.010 |
Why?
|
| Data Display | 1 | 1999 | 49 | 0.010 |
Why?
|
| Teleradiology | 1 | 1999 | 13 | 0.010 |
Why?
|
| Computer Graphics | 1 | 1999 | 77 | 0.010 |
Why?
|
| Database Management Systems | 1 | 1999 | 58 | 0.010 |
Why?
|
| Benzamides | 1 | 2004 | 1879 | 0.010 |
Why?
|
| Biomarkers, Tumor | 2 | 2009 | 10708 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 2394 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2003 | 738 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2002 | 437 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 2493 | 0.010 |
Why?
|
| Ischemia | 1 | 2000 | 400 | 0.010 |
Why?
|
| Face | 1 | 1999 | 252 | 0.010 |
Why?
|
| Skull | 1 | 1999 | 251 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2003 | 927 | 0.010 |
Why?
|
| Piperazines | 1 | 2004 | 2145 | 0.010 |
Why?
|
| Melanoma | 1 | 2013 | 5595 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 3844 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2006 | 3409 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 4481 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 4372 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2004 | 3669 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2007 | 17061 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 12033 | 0.010 |
Why?
|
| Animals | 1 | 1995 | 61956 | 0.010 |
Why?
|
| Child | 1 | 2007 | 30559 | 0.000 |
Why?
|
| Brain | 1 | 1999 | 4208 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 14617 | 0.000 |
Why?
|